Surgical Treatment of de novo Metastatic Breast Cancer
Current Breast Cancer Reports(2022)
摘要
Purpose of review De novo metastatic breast cancer (dnMBC) accounts for approximately 6% of all new breast cancers each year. While the survival benefits from removing the primary tumor in patients with MBC remain unclear, many patients still undergo surgery. The purpose of this review is to evaluate recent retrospective and prospective studies that examine the role of surgical resection of primary tumors for patients with dnMBC. Recent Findings Many retrospective analyses have suggested a survival benefit associated with surgery. However, recent prospective randomized clinical trials, both nationally and internationally, have not consistently demonstrated a survival benefit for all patients, although subgroup analyses suggest a possible survival benefit for certain subpopulations. Summary The role of surgery in the treatment of dnMBC is not fully defined. Certain subgroups may benefit from surgery as an option for the local–regional treatment of their cancers. Ongoing prospective clinical trials are evaluating these questions.
更多查看译文
关键词
De novo metastatic breast cancer,Stage IV breast cancer,Breast surgery,Local–regional treatment,Mastectomy,Survival,Breast cancer treatment
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要